期刊
DRUG DISCOVERY TODAY
卷 22, 期 8, 页码 1250-1257出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2017.05.005
关键词
-
资金
- ERC-STG grant (INTRACELLTB) [260901]
- ITN Network 'CycloN Hit' FP7-PEOPLE [608407]
- European Community (MM4TB) [260872]
- Pasteur Institute Network [PTR441]
- Agence Nationale de Recherche [ANR-14-CE08-0017, ANR-14-CE14-0024, ANR-14-CE14-0027, ANR-10-EQPX-04-01, ANR-16-CE35-0009]
- Region Les Hauts de France [12000080]
- Agence Nationale de la Recherche (ANR) [ANR-16-CE35-0009, ANR-14-CE14-0027, ANR-14-CE14-0024] Funding Source: Agence Nationale de la Recherche (ANR)
- European Research Council (ERC) [260901] Funding Source: European Research Council (ERC)
Tuberculosis (TB) remains a leading global health problem that is exacerbated by the emergence of multidrug and extensively drug-resistant Mycobacterium tuberculosis strains. Control of the disease requires novel therapeutic strategies. Modulating host homeostasis appears to be a promising approach, and recent studies have identified novel potential host targets and compounds that could be investigated for host-directed therapies (HDTs). Moreover, the recent development of intracellular high-throughput phenotypic assays makes it possible to screen large libraries of compounds to identify more rapidly new effectors for mycobacterial elimination. Technological advances combined with the novel HDT concept opens an interesting and promising research area that could ultimately deliver personalized TB treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据